“…23 For efficacious T cell therapy, both, the identification of proteins essential for cancer survival and TCR reactivity have to be addressed. 2,14,17,19,24 Utilization of TCRs from the allogeneic repertoire, exploiting a naturally occurring mechanism of self-defense, may circumvent both the requirement for affinity enhancement and anergy of T cells to tumor self-antigens. 15,25 Attempts to translate recent achievements of cellular therapy with e.g., chimeric antigen receptor T cells into the treatment of solid tumors, in particular pediatric sarcomas, has had limited success so far.…”